摘要
目的观察在多药耐药慢性乙肝患者治疗中替诺福韦酯的治疗价值。方法收集2012年1月-2014年12月多药耐药慢性乙肝患者64例,将64例患者随机分为对照组(阿德福韦酯治疗)与观察组(替诺福韦酯治疗),分析患者HBV-DNA定量变化情况及病毒学、生化学应答情况。结果两组HBV-DNA降幅、病毒学应答率、生化学应答率对比,差异有统计学意义(P〈0.05)。结论在多药耐药慢性乙肝患者治疗中替诺福韦酯价值较高。
Objective To observe the multi-resistant tenofovir ester in therapy for chronic hepatitis b patients of therapeutic value. Methods 64 cases of patients with chronic hepatitis b were chosen from January 2012 to December 2014, 64 patients were randomly divided into control group(adefovir ester treatment) and the observation group(tenofovir ester treatment), analysis of patients with HBV-DNA quantitative change and virological and biochemical responses. Results Two groups of HBV-DNA decline, virological response rates, biochemical response rates contrast, significant difference(P〈0.05). Conclusion The multi-drug resistance in patients with chronic hepatitis b treatment tenofovir ester value is higher.
出处
《中国继续医学教育》
2016年第5期169-170,共2页
China Continuing Medical Education
关键词
多药耐药
慢性乙肝
替诺福韦酯
Multi-resistant
Chronic hepatitis b
Tenofovir ester